Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort

23ME-00610 - 23andMe

J. Krystal1; A.R. Khaki2; A.I. Spira3; A.R. Abdul Razak4; D. Maslyar5; D.M. Glatt5; C.C. Hwang5; A.N. Diep5; M. Schmidt5; R. Vold5

Jul 19, 2024